Buy Paroxetine Online in Canada

What Paroxetine is (brief)

Paroxetine is primarily used to treat depressive disorders presenting with persistent low mood, anhedonia, fatigue, and cognitive or psychomotor slowing, often accompanied by anxiety. It is also prescribed for generalized anxiety, panic, social anxiety, obsessive-compulsive, and post-traumatic stress disorders. Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking reuptake, producing antidepressant and anxiolytic effects over weeks.

As with other SSRIs, the pharmacologic goal is to restore serotonergic signaling within brain circuits that regulate mood and fear. Paroxetine is formulated for oral administration and is available in several dosage strengths to support individualized therapy. Its relatively steady pharmacokinetic profile supports once-daily dosing in many patients.

What it is used for

Approved indications include major depressive disorder and the anxiety spectrum described above. In adults and select pediatric populations, paroxetine is considered when first-line options are inadequate or poorly tolerated, and it may be used for OCD, panic disorder, social anxiety disorder, or PTSD under specialist supervision. Therapeutic response typically emerges after several weeks of treatment, with consideration of sustained therapy to maintain remission.

The drug acts through restoration of serotonin signaling and may require dose adjustments based on response and tolerability. Dosing is individualized and guided by comorbid conditions, concomitant medications, and risk of adverse effects. In clinical practice, gradual titration and adherence to therapy are essential to optimize outcomes.

Contraindications and precautions

Contraindications include known hypersensitivity to paroxetine or any formulation components. Concomitant use with monoamine oxidase inhibitors or within 14 days of MAOI discontinuation is contraindicated due to the risk of serious serotonergic reactions. Co-administration with linezolid or intravenous methylene blue is also contraindicated. Pregnancy and lactation require careful risk-benefit assessment; paroxetine carries potential fetal harm and should be used during pregnancy only if clearly needed, with cessation considered if pregnancy occurs. Paroxetine is excreted in breast milk and may affect a nursing infant; alternatives should be discussed.

Caution is advised in patients with hepatic impairment, as reduced clearance can prolong exposure and increase adverse effects. In the elderly, hyponatremia and SIADH are potential risks; baseline and periodic sodium monitoring may be warranted. Paroxetine strongly inhibits hepatic CYP2D6; coadministration with drugs that rely on this pathway (for example, tamoxifen, codeine, or certain beta-blockers) can alter exposure and efficacy and may require dose adjustment or alternative therapy.

Careful monitoring is recommended for suicidality and behavior changes, particularly during initiation or dose changes. Abrupt discontinuation of paroxetine can precipitate withdrawal symptoms, including dizziness, insomnia, flu-like symptoms, irritability, or sensory disturbances; gradual tapering over at least several days is advised. Patients and caregivers should be instructed to seek urgent care for signs of serotonin syndrome, liver injury, or severe allergic reaction.

Side effects by frequency

Common adverse effects during initial treatment include nausea, diarrhea or loose stools, dry mouth, dizziness, somnolence or insomnia, and fatigue. Sexual dysfunction, such as decreased libido and delayed ejaculation, is frequently reported and can persist with continued therapy. Appetite changes and weight fluctuations may also occur.

Less frequent but noteworthy adverse effects include excessive sweating, tremor, headaches, and abdominal discomfort. Visual disturbances or confusion can occur in susceptible individuals, and bruising or bleeding may be observed with concurrent antiplatelet therapy. Symptom onset is usually early and may attenuate with dose stabilization.

Serious but uncommon risks include serotonin syndrome with other serotonergic agents, hyponatremia and SIADH, extrapyramidal symptoms or akathisia, and manic or hypomanic switches in patients with latent bipolar disorder. Rare QT interval prolongation and cardiac conduction abnormalities have been reported at high doses or in predisposed patients. Any new or worsening neuropsychiatric signs warrants prompt evaluation.

Interactions with other substances

Interactions center on serotonergic and psychopharmacologic pathways. Co-administration with monoamine oxidase inhibitors, linezolid, or methylene blue is contraindicated; combining these agents with paroxetine increases the risk of serotonin syndrome. Concurrent use of other SSRIs, SNRIs, or triptans requires careful risk assessment and monitoring.

Paroxetine is a strong inhibitor of CYP2D6 and can elevate exposure to substrates such as tamoxifen, codeine, tramadol, metoprolol, and certain antipsychotics. In patients receiving tamoxifen for breast cancer, paroxetine can reduce the formation of the active metabolite endoxifen and potentially diminish efficacy. Dose adjustments or alternative antidepressants should be considered in such cases.

Bleeding risk may be increased when paroxetine is combined with NSAIDs, antiplatelet agents, or anticoagulants. CNS depressants, including alcohol, can potentiate sedation and motor impairment. Caution is advised when coadministering with other serotonergic or dopamine-modulating medicines due to possible additive adverse effects or mood destabilization.